Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market Growth Potential: How Will Market Size Change Through 2030?
The market for warm autoimmune hemolytic anemia (wAIHA) treatments has experienced robust expansion in recent years. Projected to increase from $0.6 billion in 2025 to $0.65 billion in 2026, this growth reflects a compound annual growth rate (CAGR) of 9.2%. This historical uptrend is largely driven by factors such as dependence on corticosteroid treatments, a scarcity of available therapeutic options, hospital-centered management of autoimmune conditions, reliance on blood transfusions, and limited public awareness of the disease.
The market for warm autoimmune hemolytic anemia (wAIHA) treatments is projected to experience substantial expansion in the coming years, reaching a valuation of $0.93 billion by 2030, expanding at a compound annual growth rate (CAGR) of 9.2%. This anticipated growth during the forecast period is driven by advancements in biologic drug development, enhancements in autoimmune diagnostic techniques, the broadening application of precision medicine, an increase in the elderly population, and the development of specialized hematology care. Key trends shaping this period include a greater reliance on monoclonal antibody therapies, a higher uptake of steroid-sparing treatment options, the growth of personalized autoimmune approaches, an expanding role for intravenous immunoglobulin (IVIG) in acute care settings, and refined diagnostic and monitoring standards.
Download A Free Sample Report For Comprehensive Market Insights:
Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market Growth Momentum: Which Factors Are Influencing Demand?
The growth of the warm autoimmune hemolytic anemia (WAIHA) treatment market is anticipated to be driven by rising healthcare expenditure moving forward. Healthcare expenditure encompasses the total resources allocated to health services, covering prevention, diagnosis, treatment, and disease management by individuals, governments, and organizations. Advances in medical technology are pushing healthcare spending upward, as innovative diagnostic tools and therapies typically involve higher costs for development, implementation, and ongoing patient care. Such expenditure supports WAIHA treatment by funding research, enabling access to advanced diagnostics, and ensuring the availability of specialized therapies to manage and control the condition. For example, in May 2024, the Office for National Statistics, a UK-based government agency, reported that in real terms, long-term health and social care spending rose by 2.8% in 2022, while overall healthcare expenditure increased by 5.6% in 2023. Consequently, the rising healthcare expenditure is fueling growth in the warm autoimmune hemolytic anemia treatment market.
Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market Categorization By Product Type And Application
The warm autoimmune hemolytic anemia (waiha) treatment market covered in this report is segmented –
1) By Treatment Type: Corticosteroids, Monoclonal Antibodies, Intravenous Immunoglobulin (IVIG), Blood Transfusions, Splenectomy
2) By Route Of Administration: Oral, Intravenous, Subcutaneous
3) By Patient Demographics: Children, Adults, Geriatric
4) By Therapeutic Area: Primary Autoimmune Disorders, Secondary Autoimmune Disorders, Genetic Predisposition
5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Corticosteroids: Prednisone, Dexamethasone, Methylprednisolone
2) By Monoclonal Antibodies: Rituximab, Sutimlimab, Bortezomib
3) By Intravenous Immunoglobulin: Standard IVIG, High-Dose IVIG Therapy, Pooled Plasma-Derived Immunoglobulins
4) By Blood Transfusions: Leukoreduced RBC Transfusions, Emergency Transfusions, Phenotypically Matched RBC Transfusions
5) By Splenectomy: Laparoscopic Splenectomy, Prophylactic Treatments Post-Splenectomy, Open Splenectomy
Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market Trends Reshaping Industry Growth
Key industry players in the warm autoimmune hemolytic anemia (WAIHA) treatment market are prioritizing the development of advanced therapies, including monoclonal antibodies, aimed at fulfilling unmet clinical requirements and enhancing patient outcomes. These monoclonal antibodies are artificially created proteins designed to target particular immune cells or pathways, thereby limiting the destruction of red blood cells in warm autoimmune hemolytic anemia. A notable example is the July 2023 announcement by IASO Biotechnology, a biopharmaceutical company based in China, regarding the U.S. Food and Drug Administration (FDA) approval of IASO-782 Injection for clinical studies targeting autoimmune hematological conditions in the United States, specifically warm autoimmune hemolytic anemia (WAIHA) and primary immune thrombocytopenia (ITP). This fully human monoclonal antibody targets CD19 and incorporates Fc mutations to enhance antibody-dependent cellular cytotoxicity (ADCC) activity while preserving other Fc functions. It works by selectively eliminating CD19+ B cells, plasmablasts, and certain plasma cells that are involved in generating auto-reactive antibodies. Because of its unique mechanism of action, IASO-782 holds potential for treating autoimmune disorders driven by pathogenic B cells and plasma cells, such as ITP and AIHA.
Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market Company Landscape And Strategic Competition
Major companies operating in the warm autoimmune hemolytic anemia (waiha) treatment market are F. Hoffmann-La Roche Ltd., Sanofi S.A., Novartis AG, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Agios Pharmaceuticals Inc., Incyte Corporation, Mallinckrodt Pharmaceuticals, Xencor Inc., Annexon Inc., Rigel Pharmaceuticals Inc., Apellis Pharmaceuticals Inc., Momenta Pharmaceuticals Inc., Immunovant Inc., Zenas BioPharma Inc., Alexion Pharmaceuticals Inc., CSL Behring, Grifols S.A., Octapharma AG, Kedrion Biopharma, LFB Group, ADMA Biologics Inc., Pfizer Inc., Bristol-Myers Squibb Company, Amgen Inc.
Access The Complete Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market Report:
Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market Largest Region By Revenue And Market Share
North America was the largest region in the warm autoimmune hemolytic anemia (WAIHA) treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the warm autoimmune hemolytic anemia (waiha) treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model